
Esperion Therapeutics (ESPR) Stock Forecast & Price Target
Esperion Therapeutics (ESPR) Analyst Ratings
Bulls say
Esperion Therapeutics Inc. has reported substantial progress in its financial performance, highlighted by a 53% year-over-year increase in product revenue to $31.1 million for the most recent quarter, driven by notable retail prescription growth. The company's strategic partnership with Daiichi Sankyo Europe has resulted in a significant 19% sequential increase in royalty revenues, reflecting strong prescription growth for its products NILEMDO and NUSTENDI. Furthermore, improved commercial and Medicare coverage rates above 92% and 65%, respectively, indicate growing confidence from healthcare providers, promising an optimistic sales outlook for the company's therapeutic offerings in the coming quarters.
Bears say
Esperion Therapeutics Inc. faces a negative outlook primarily due to its historical pattern of financial losses and the lack of established profitability, which raises concerns about its long-term viability. Additionally, the company has been forced to incrementally lower its sales estimates, indicating potential challenges in meeting market expectations and sustaining revenue growth. Furthermore, the risk of competing breakthrough therapies could threaten the relevance of Esperion’s existing products, adding to the uncertainties surrounding its financial future and maintaining balance sheet stability.
This aggregate rating is based on analysts' research of Esperion Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Esperion Therapeutics (ESPR) Analyst Forecast & Price Prediction
Start investing in Esperion Therapeutics (ESPR)
Order type
Buy in
Order amount
Est. shares
0 shares